Velmanase Alfa

Summary

Velmanase Alfa (CHEMBL4298010) is an approved enzyme (ATC A16AB15); indicated across 2 conditions including alpha-mannosidosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• ATC class: A16AB15
• Indications: 2 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298010
Name	Velmanase Alfa
Type	Enzyme
Max phase	4
ATC	A16AB15

Also known as: A16AB, CHF-LMZYMAA1, CHFLMZYMAA1, Lamazym, Lamzede, R-h-laman, Recombinant human laman, Rhlaman, Velmanasa alfa, Velmanase alfa, Velmanase alfa-tycv, VELMANASE ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
alpha-mannosidosis	4	MONDO:0009561	MONDO:0009561

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE3	5
PHASE2	2
Not specified	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01681953	PHASE3	COMPLETED	A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis
NCT01908712	PHASE3	COMPLETED	Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients
NCT01908725	PHASE3	COMPLETED	Lamazym Aftercare Study
NCT02478840	PHASE3	COMPLETED	Evaluation of Long-term Efficacy of Treatment With Lamazym
NCT04031066	PHASE3	WITHDRAWN	Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis
NCT01285700	PHASE2	UNKNOWN	Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
NCT01681940	PHASE2	COMPLETED	Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis
NCT01268358	PHASE1	COMPLETED	Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
NCT04959240	Not specified	AVAILABLE	Expanded Access to Velmanase Alfa
NCT06184503	Not specified	RECRUITING	Analysis of Velmanase Alfa (Lamzede®)’s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).